Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $127 to $123.
Needham Maintains Buy on Conmed, Lowers Price Target to $123
Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $127 to $123.
Related Posts
Catalent, Pinduoduo And 3 Stocks To Watch Heading Into Monday
With US stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
O-I Glass Sees Q3 EPS $0.68-$0.73 Vs $0.64 Est.; Q4 EPS $0.25-$0.35; FY23 EPS $3.10-$3.25 Vs $3.17 Est
2023 Outlook$ millions except per share data ACTUALGUIDANCEYTD233Q234Q23FY23Sales Volume Growth (in Tons)▼ 9%▼ MSD/HSD▼ LSD/MSD▼ MSD/HSDAdjusted Earnings Per Share$2.17$0.68 -
Markets Dip, Signaling Pause In Rally As Focus Shifts To Next Week’s Fed Decision: Analyst Says Brace For More Volatility Near Term
Risk aversion escalated on Wall Street Friday, with all major indices trading in the red, as investors remain skeptical about the stability of the banking sector in the wake of recent turmoil in the U.S. and Europe.
Cues From Friday's Trading: